哪里想瘦打哪里！FDA批准Kythera注射药物该公司在即

你才双下巴，你全家都双下巴！其实质大方欲人皆有之。如果说赘肉是每一个希望享有真正身材的“妹纸”或“汉纸”的大敌，那么一个喜感十足的双下巴却是是这些人的生死仇敌了。每一分钟，国外都有人为自己的一张大饼脸而深感烦恼，虽然享有一个肉感十足的双下巴摸刚才是一挺有肉感的，但是还是有很多人的心理素质使其不能承受一个双下巴之重。您可千万别哭，这甚至从未催生造出一个浩大的市场。根据American皮肤麻醉Association的追查分析显示，68%的American人对自己的双下巴坚称了“不感兴趣”之情。而有感于，近期Kythera子公司向FDA送交了其最初铲除双下巴的美容注射式本品ATX-101。这种本品完成了许多“胖纸”梦寐以求的动态，哪里想瘦打哪里，却是是定时减肥。不要以为这种近乎任性的本品只是一个哭话，在FDA下属的皮肤和内科本品专员会的无记名投票之中，科学家可是以17：0的超高高票一致采纳其主板。确实是因为这些科学家之中也有很多遭受双下巴之苦吧。FDA也将著手于月内的5月13日之前对其作造出最后重新考虑。如果一切顺利的话，Kythera子公司著手于月内下半年将该的产品主板，分析政界人士预计这一本品的销售额将超过3亿美元之多。随着美容本品市场的逐渐增大，Kythera子公司却是是下了一步好棋。子公司于月份以8400万美元的单价从其前合作伙伴拜耳手之中归还给了这种本品的全部权利。而Kythera子公司也希望更进一步为借此机会在美容本品市场之中攻城拔寨。就在上个月，Kythera子公司和Actelion子公司达成协议价值2700万美元的合作协约，所设计一种失败过的促炎症本品，而这种本品被认为意味著整合造出一种放射治疗脱发的本品。概要法文另据：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.